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Excitotoxicity is considered to be an important mechanism involved in various neurodegenerative diseases in the central
nervous system (CNS) such as Alzheimer’s disease (AD). However, the mechanism by which excitotoxicity is implicated in
neurodegenerative disorders remains unclear. Kainic acid (KA) is an epileptogenic and neuroexcitotoxic agent by acting on speciﬁc
kainate receptors (KARs) in the CNS. KA has been extensively used as a speciﬁc agonist for ionotrophic glutamate receptors
(iGluRs), for example, KARs, to mimic glutamate excitotoxicity in neurodegenerative models as well as to distinguish other iGluRs
such as α-amino-3-hydroxy-5-methylisoxazole-4-propionate receptors and N-methyl-D-aspartate receptors. Given the current
knowledge of excitotoxicity in neurodegeneration, interventions targeted at modulating excitotoxicity are promising in terms of
dealing with neurodegenerative disorders. This paper summarizes the up-to-date knowledge of neurodegenerative studies based
on KA-induced animal model, with emphasis on its potentials and limitations.
1.Introduction
Excitotoxicity is involved in a variety of neurodegenerative
disorders in the central nervous system (CNS) includ-
ing Alzheimer’s disease (AD), Parkinson disease (PD),
amyotrophic lateral sclerosis (ALS), and multiple sclerosis
(MS). In the past decades, great achievements have been
obtained in elucidating excitatory signaling pathways, yet
the mechanism by which glutamate receptors is implicated
in neurodegenerative disorders remains unclear. Kainic
acid (KA), an analog of excitotoxic glutamate, can elicit
selective neuronal death in the brain of rodents, of which
the pathological changes partially mimic neurodegenera-
tion in the CNS. Thus, KA-induced neurodegeneration
in rodents has been used as a model for exploring the
pathogenesis of excitotoxicity in neurodegenerative disor-
ders.
2. Generic Characteristicsof
KAandKAReceptors(KARs)
KA was originally isolated from the seaweed called “Kainin-
sou” or “Makuri”. The molecular formula of KA are
C10H15NO4 and the molar mass of KA is 213.23 (Figure 1).
Initially, KA was used as an antihelminth compound to
remove worms from the gut. Subsequent studies indicated
that KA is a nondegradable analog of glutamate and a potent
neurotoxin [1]. KA exerts its neuroexcitotoxic and epilep-
togenic properties by acting on kainate receptors (KARs).
Upon binding to KARs, KA induces a number of cellular
events, including the inﬂux of cellular Ca2+,p r o d u c t i o no f
reactive oxygen species (ROS), and mitochondrial dysfunc-
tion leading to neuronal apoptosis and necrosis [2]. KA has
been extensively utilized as a speciﬁc agonist for ionotropic
glutamate receptors (iGluRs); that is, KARs to mimic the2 Journal of Biomedicine and Biotechnology
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Figure 1: The molecular structure of kainic acid (2-carboxy-4-
isopropenylpyrrolidin-3-ylacetic acid, KA). The molecular formula
of KA are C10H15NO4 and the molar mass of KA is 213.23g/mol.
eﬀect of glutamate in neurodegenerative models, as well as to
distinguish other ionotropic receptors for glutamate. KARs
mediate most of kainate-induced seizures and excitotoxic
neuronal death, whereby serving as a promising therapeutic
target for neurodegeneration.
Two broad categories of glutamate receptors (GluRs),
that is, iGluRs and metabotropic GluRs (mGluRs), dif-
fer with reference to their functions. There are three
major subtypes of iGluRs: N-methyl-D-aspartate recep-
tor (NMDARs), α-amino-3-hydroxy-5-methylisoxazole-4-
propionatereceptor (AMPARs),andKARs,termedaccording
to the types of synthetic agonists [3]. The latter two subtypes
are usually referred to together as non-NMDA receptors.
The KARs family is divided into two subfamilies, including
GluR5-7 and KAR1-2. A new nomenclature for iGluR family
has been recently recommended by the International Union
of Pharmacology Committee on Receptor Nomenclature
and Drug Classiﬁcation (NC-IUPHAR) [4]. In view of the
popularity of the conventional nomenclature in previous
studies, the present paper follows its conventional use.
3. Featuresof KA-Induced Neurodegenerative
Animal Model
Systemic (intravenous or intraperitoneal), intranasal, or
local administration of KA results in a series of clini-
cal manifestations and pathological changes in rodents,
including recurrent seizures, behavioral changes of rodents,
oxidative stress including the generation of ROS and reactive
nitrogen species (RNS), hippocampal neuronal death and
glial activation, and so forth [2].
3.1. KA Induces Recurrent Seizures and Behavioral Changes
in Rodents. In rodents, systemic administration of KA leads
to a well-characterized seizure syndrome [5, 6]. During
the ﬁrst 20–30 minutes, the animals show “staring” spells,
followed by head nodding. Then, they stand upright and fall
down,withwet-dogshakesforaround30minutes.Onehour
after KA administration, the animals start to present with
recurrent limbic motor seizures. The limbic seizures then
develop into status epilepticus and lasted 1-2 hours [7].
After KA administration, rodents show behavioral
changes in the water maze, the object exploration tasks, and
the open-ﬁeld test in association with selective damage in the
hippocampus. Deﬁciency in short-term spatial memory and
long-termspatiallearning,ahigherdegreeofanxiety[8],and
depression-like behaviors were also observed [9]. Physical
exercise and selective cyclooxygenase (COX)-2 inhibitors like
celecoxibmayhelptoenhancethefunctionrecovery[10,11].
3.2.SelectiveHippocampalNeurodegenerationinRodentsafter
KA Challenge. Among the agents used to selectively destroy
hippocampal neurons, ibotenic acid (IBO) and N-methyl-
D-aspartate (NMDA) are nonspeciﬁc in acting on diﬀerent
cell types and usually these toxins do not cause seizures.
In contrast, focal injection of KA resulted in hippocampal
damagethatoccurredprimarilyintheCA3area[12].Similar
selective vulnerability to KA was also seen when KA is
administered via systemic injection. Selective vulnerability
of hippocampal neurons was related to the distribution
of the AMPARs/KARs in the brain [13]. KARs are most
abundant in CA3 region and the activation of KARs can
induce the production of ROS and compromise the function
of mitochondria in the region [14, 15]. The stimulation of
KARs excites CA3 neurons directly and increases glutamate
eﬄux [16, 17]. Systemic injection of KA produced extensive
neuronal death, primarily within the hippocampus hilus,
CA3, and CA1 areas [18]. The hilar neurons are sensitive
to KA-induced excitotoxicity, but neuronal loss in the other
hippocampal areas varies between animal species and strains
[19, 20]. KA at higher doses can also induce neurotoxicity in
the medial amygdaloid nuclei [21].
KA-caused neuronal death involves endoplasmic retic-
ulum (ER) stress, activation of ER sensor proteins, and
induction of the fragmentation of the ER membrane [22], as
well as Ca2+ overload [2]. C-jun N-terminal kinase (JNK)3
plays a detrimental role whereas other MAPKs like p38 and
extracellular signal-regulated kinases 1/2 (ERK 1/2) seem to
play a beneﬁcial role [23]. Ikappa B kinase (IκB)/nuclear
factor-kappa B- (NFκB-) dependent microglia activation
contributes to KA-induced hippocampal neuronal death
in vivo through induction of inﬂammatory mediators like
tumor necrosis factor (TNF)-α and interleukin (IL)-1β [24].
3.3. Glial Activation after KA Treatment. KA binds to KARs
expressed on neurons and microglia, leading to (1) rapid
Ca2+ inﬂux, (2) activation of Ca2+-dependent enzymes and
generation of ROS and RNS, (3) excessive Ca2+, ROS and
RNS lead to mitochondrial dysfunction, and (4) nuclear
condensation and DNA fragmentation. Alternatively, intense
Ca2+ overload can directly cause mitochondrial swelling
and damage, causing acute neuronal cell death [2]. KA-
induced neuronal death is accompanied by the activation
of gliocytes, that is, microglia and astrocytes, characterized
by the clustering of activated gliocytes in the hippocampal
lesions [25, 26].
Microglia are the main eﬀector cells of the inﬂammatory
responses in the CNS, exert their functions as phagocytes,
and interact with other gliocytes and neurons [27]. The
physiological role of microglia can be partly linked to neu-
roprotection whereas under pathophysiological conditions,
microglia may become activated and secrete a great amount
of proinﬂammatory cytokines, chemokines, complements,Journal of Biomedicine and Biotechnology 3
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Figure 2: KA-induced microglial activation. Activated microglia express MHC class I and II, costimulatory molecules (CD80 and CD86),
chemokine receptors (CCR2, 3, 5, CXCR3, 4, etc.), cytokine receptors (IL-10R, IL-12R, IL-18R, IFNgR, TNFR, TGFβR, etc.), complement
receptors (FCγRI-III and CR1, 3, 4, etc.), and prostaglandin receptors, produce complements, prostaglandins, cytokines (IL-1, IL-6, IL-
10, IL-12, IL-18, TNF-α,T G F - β, etc.), chemokines (IP-10, MIP-1α, MIP-1β, MCP-1, IL-8, RANTES, etc.), ROS, and RNS, and secrete
neutrophins (NGF, BDNF, and NT-3, 4, etc.), proteases, and excitatory amino acids, and so forth, which may either contribute to excitotoxic
damage or be protective against KA damage. IL: interleukin; CCR: C-C chemokine receptor; CXCR: CXC chemokine receptor; IFNgR:
interferon gamma receptor; TNF: tumor necrosis factor; TGF: transforming growth factor; IP: Interferon gamma-inducible protein; MIP:
macrophage inﬂammatory protein; MCP: monocyte chemotactic protein; RANTES: regulated upon activation, normal T-cell expressed and
presumably secreted; NGF: nerve growth factor; BDNF: brain-derived neurotrophic factor; NT: neurotrophin.
and so forth [28]. Activated microglia may play a neuro-
protective role in MS and its animal model, experimental
autoimmuneencephalomyelitis(EAE),byfacilitatingrepara-
tory and regenerative processes [29]. However, in other neu-
rodegenerative diseases such as AD and PD, microglia may
initiate and aggravate the disease process through secreting
proinﬂammatory and cytotoxic factors [30, 31]. In KA-
induced excitotoxic neurodegeneration, activated microglia
express MHC class I, MHC class II, and costimulatory
molecules, produce complements, cytokines (IL-1, IL-6, IL-
12, IL-18, TNF-α, etc.), chemokines, ROS, and RNS, and
secrete proteases and excitatory amino acids, which con-
tributetotheneuronaldeath[27,28,32](Figure 2).Stannio-
calcin 2 (STC2), the paralog of STC1, exerts neuroprotective
actions against excitotoxic insults of KA through direct
inhibition of microglial activation [33]. Despite the impor-
tant role of microglia in KA-induced neurodegeneration,
evidence is lacking that microglia participates in initiating
the inﬂammatory and degenerative process. Seemingly, acti-
vation of microglia is just a “byproduct” of KA-induced exci-
totoxicity, but serves as an “accomplice” in this process [34].
Astrocytes were formerly regarded as passive supporters
of neurons for decades. However, a new concept of neuron-
glial intercommunication that astrocytes play a dynamic
role by integrating neuronal inputs and modulating synaptic
activity,wherebycontributingtoneurodegenerativedevelop-
ment, has been recently acknowledged [35, 36]. Astrocytes
can prevent neurons from death and promote proliferation
and diﬀerentiation of precursor cells by producing growth
factors [37–39]. Moreover, astrocytes express functional
receptors for the excitatory neurotransmitters like iGluRs
[40].Inpathologicalconditions,astrocytesmaycontributeto
braindamagebyreleasingROSandproinﬂammatoryfactors.
Failure in water transport also triggers brain edema, reversal
of neurotransmitter transporters, and Ca2+-dependent exo-
cytosis. Furthermore, the opening of high-permeability plas-
malemmal channels contributes to glutamate excitotoxicity
[41]. The expression of glial ﬁbrillary acidic protein (GFAP),
a marker for astrogliosis, was shown to steadily increase as
early as one day after intrahippocampal or intraperitoneal
injection of KA [42, 43]. Aged astrocyte speciﬁcally induced
substance (OASIS) is known to be expressed on astrocytes
and involved in the ER stress [44], which plays an important
role in attenuating neuronal damage induced by KA [45].
Upregulated transcription factors in astrocytes, including
NF-κB and nuclear factor erythroid-2-related factor 2
(Nrf2) induce the expression of neuroprotective molecules
[46, 47].4 Journal of Biomedicine and Biotechnology
3.4. KA-Mediated Oxidative Stress. KA receptors have both
presynaptic modulatory and postsynaptic excitatory actions
[48, 49] .T h ea c t i v a t i o no fK Ar e c e p t o r sl e a d st om e m b r a n e
depolarization and increased inﬂux of cellular calcium,
which are required to trigger the cascade of neuronal
death [50]. ROS/RNS have been implicated in the patho-
genesis of various neurodegenerative disorders [51]. KA
administration increases the generation of ROS and RNS.
The increased formation of thiobarbituric acid-reactive
substances (TBARS) and decreased total antioxidant status
(TAS) in the cerebral cortex, cerebellum, and brain stem of
rats subjected to KA indicate the presence of oxidative stress
in excitotoxicity [52]. The exact mechanisms regarding the
increased production of nitric oxide (NO) in excitotoxicity
are not well established. However, stimulation of KARs
induces NO release, which, in turn, modulates glutamate
transmission [53]. NO may induce changes in neuronal
signaling pathways [54]. Generation of other free radicals
alsocontributestoneuronaldamage[55].KAinducesimme-
diate production of COX-2 that is involved in hippocampal
neuronal death [56]. COX-2 facilitates the recurrence of
hippocampal seizures and stimulates hippocampal neuronal
loss after KA administration [57, 58]. PGE(2), the synthesis
of which is dependent on COX, is pathologically increased
in the brain after KA treatment, in close association with
neuronal death [59]. In addition, seizure-induced products
of lipid peroxidation, such as F(2)-isoprostanes and isofu-
rans, play critical roles in the initiation and modulation of
inﬂammation and oxidative stress, serving as reliable indices
of oxidative stress in vivo [60].
3.5. KA-Enhanced Inﬂammatory Mediator Production. Neu-
rodegeneration is associated with increased inﬂammatory
mediators in the CNS such as in AD, MS, and so forth [61,
62]. Activated microglia and astrocytes after KA treatment
release a large amount of inﬂammatory mediators such as
NO, IL-6, IL-12, TGF-β,T N F - α, IL-18, and IL-1β [28, 63,
64]. Manipulation of inﬂammatory mediators may aﬀect the
outcome with regard to seizure activity, behavioral changes,
aswellastheneuropathologicalconsequencesinKA-induced
neurodegeneration [65]. Important inﬂammatory mediators
including NO, IL-6, TGF-β,T N F - α, IL-12, IL-18, and IL-1β
are herein summarized.
The production of NO represents one of the principle
features of activated macrophage/microglia, and NO is a
major eﬀector in the innate immunity [66]. NO can be
formed enzymatically from L-arginine by inducible NO syn-
thase (iNOS) in neuroglia [67]. KA administration increases
the generation of ROS and RNS by neuroglia. Microglia
can produce large amounts of soluable factors like NO [68].
Elevated production of NO by increased activity of iNOS is
thought to contribute to KA-induced neuronal damage [69].
iNOS-deﬁcient mice are resistant to KA-induced neuronal
death [70]. Similarly, pretreatment with aminoguanidine,
a selective iNOS inhibitor, signiﬁcantly suppressed KA-
induced neuronal death in the hippocampal CA3 area with
concomitant decrease in iNOS expression and microglial
activation [70].
IL-6, which is secreted by macrophages, dendritic cells,
T cells, and so forth, bears both pro- and anti-inﬂammatory
functions. IL-6 was initially categorized into a T helper (Th)
1 cytokine [71]. However, IL-6 can induce IL-4 production
by na¨ ıve Th0 cells and their diﬀerentiation into eﬀector
Th2 cells [72]. IL-6 appears to be a critical factor in early
phases of CNS insults, taking part in the orchestration of
attempts for tissue repair [69]. Levels of IL-6 are increased
in the cerebrospinal ﬂuid (CSF) in humans after tonic-clonic
seizures [73]. IL-6 mRNA is increased in the hippocampus,
cortex, amygdale, and meninges, and IL-6 receptor is upreg-
ulated in the hippocampus in the rat brain after KA-induced
status epilepticus [73]. Neuronal death is more pronounced
when IL-6 is produced in limbic seizures induced by
KA [26]. Upregulated expression of IL-6 represented an
endogenous neuroprotective mechanism against NMDAR-
mediated injury in cerebral ischemia [74]. IL-6 knockout
mice exhibit signiﬁcantly higher seizure susceptibility to
NMDA, AMPA, and KA, and the excitatory amino acid
system seems more active in the CNS of IL-6 deﬁcient
mice [75]. Speciﬁcally, IL-6 deﬁciency increases neuronal
injury and impaired the inﬂammatory response after KA
treatment, characterized by reduced reactive astrogliosis and
microgliosis versus increased morphological hippocampal
damage, oxidative stress, iNOS expression, and apoptotic
neuronal death [76].
IL-12 consists of p35 and p40 subunits, which form
the bioactive IL-12p70 when combined together. IL-12 is
required for the induction of IFN-γ production, critical for
the polarization of the Th1 immune response. In EAE, the
proinﬂammatory cytokines IL-12, IFN-γ,T N F - α,I L - 1 β,I L -
6, and IL-18 are involved in the initiation and development
of the local immune responses in the CNS [77]. IL-12
can be produced by activated microglia in response to KA,
and IL-12p35 deﬁciency may alleviate hippocampal injury
upon KA challenge, indicating a critical role of IL-12 in
excitotoxin-induced brain injury [65]. Moreover, expression
IL-12wasincreasedinIL-18deﬁcientmiceascomparedwith
controls in association with increased microglial activation,
suggesting that the null role of IL-18 in excitotoxic injury
may be compensated by the upregulated levels of IL-12 [78].
TGF-β bears anti-inﬂammatory, immunosuppressive,
and neuroprotective features. It can downregulate
(micro)glial cytokine production, for example, IL-1
and TNF-α [69]. TGF-β1 mRNA in the regenerating
neurons is correlated with glial activation [79]. Exogenous
administration of TGF-β1 protects excitotoxic lesions and
neuronal death [80]. TGF-β1 mRNA is also increased in
the hippocampus after KA-induced seizures, particularly in
the areas of neurodegeneration [81]. TGF-β3 is upregulated
in response to KA, and exogenous TGF-β3 signiﬁcantly
attenuates KA-induced seizures and neuronal loss in a
dose-dependent manner, indicating a protective role of
TGF-β3[ 82].
TNF-α is mainly produced by microglia and astrocytes
in the CNS. KA-activated microglia expressed high levels of
TNF-α mRNA and protein. As with many other cytokines,
TNF-α bears neuroprotective properties in contrast to its
well-known deleterious role as a proinﬂammatory cytokine,Journal of Biomedicine and Biotechnology 5
which implies an intricate biological balance in immune
and inﬂammatory responses mediated by TNF-α [83]. The
mechanisms by which TNF reduces brain injury may involve
the upregulation of proteins, such as neuronal apoptosis
inhibitor protein (NAIP), which maintains calcium home-
ostasis or reduces free radical generation [84]. The protective
roles of TNF-α in KA-induced neurodegeneration can also
be mediated via TNFR2 signaling pathway [85]. However,
inconsistent ﬁndings suggested that TNF-α derived from
KA-activated microglia can increase the excitotoxicity of
hippocampal neurons and can induce neuronal apoptosis in
vitro and in vivo [86].
IL-18 is a proinﬂammatory cytokine which can enhance
postsynaptic AMPAR responses in CA1 pyramidal neurons
via the release of glutamate, thereby facilitating basal hip-
pocampal synaptic transmissions [87]. IL-18 knockout mice
showed a diminished microglial activation and reduced
dopaminergic neuronal loss after acute 1-methy-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) treatment [88]. In KA-
induced excitotoxicity, IL-18 immunoreactivity was found
in the hippocampal microglia of mice whereas IL-18R
immunoreactivity was observed in astrocytes. Levels of IL-18
and IL-18R in the hippocampus were upregulated progres-
sively from day 1 and reached the peak on day 3 post-KA
treatment [89]. We found that exogenous administration of
IL-18 aggravated KA-induced injuries in C57BL/6 mice, and
IL-12 could compensate the function of IL-18 and worsen
seizure severity as well as hippocampal neurodegeneration in
IL-18 deﬁcient mice [78].
IL-1β, a proinﬂammatory cytokine produced in abun-
dance by activated microglia, acts as a regulatory factor
in the multiple connections among the immune, nervous,
and endocrine systems. IL-1β exerts its eﬀects through IL-
1 receptor type I (IL-1RI) and IL-1 receptor accessory
protein (IL-1RAcP) [90]. IL-1β plays a pivotal role in the
neuroinﬂammation associated with certain forms of neu-
rodegeneration, including cerebral ischemia and excitotoxic
brain injury [91]. Compelling evidence in experimental
neurodegenerative models indicates that IL-1β is pivotal in
the excitotoxicity leading to neuronal death [92]. Primary
cultured microglia are signiﬁcantly activated by KA with
increased IL-1β levels [93]. IL-1β can mediate KA-induced
excitotoxic injuries to hippocampal neurons in vitro and in
vivo [93].
4. NeurodegenerativeAnimalModelInducedby
IntranasalAdministration of KA:
Our Experience
C57BL/6 mice are commonly used for transgenic studies,
while they are resistant to systemic administration of KA
(intravenous or intraperitoneal). However, Chen et al. in our
group,developedamodelofKA-inducedneurodegeneration
by intranasal administration of KA into C57BL/6 mice [94].
This model provides a valuable tool to explore the role of
excitotoxicity in neurodegeneration using transgenic mice
with C57BL/6 background. Within 15 minutes after KA
administration, C57BL/6 mice are catatonic and staring,
followed by myoclonic twitching, frequent rearing, and
repeated falling. Approximately 30–40 minutes after admin-
istration, the mice present with status epilepticus, which
lasts 1–5 hours. Some serious cases die from seizures. Then
the mice assume a hunched posture and remain immobile
for additional few hours [78]. As to behavioral changes,
intranasal administration of KA induced elevated levels of
spontaneous activity in the open-ﬁeld test [94].
The mechanism as regards how KA induces excitotoxic
neurodegeneration through intranasal administration is
underclariﬁed whereas we have several speculations. Firstly,
KA may reach the hippocampus via passive diﬀusion,
a route utilized extensively in both clinical practice and
laboratory investigations [95]. Secondly, KARs were found
in olfactory nerves and the olfactory bulb [96]. Protracted
postsynaptic stimulation induced by KA can be relayed
through projections to the hippocampus and thus result in
neuronal damage. Thirdly, KA may directly enter the CSF
via the nasal cavity, since the CSF has direct connection with
the olfactory bulb [97]. Additionally, drugs with a molecular
weight of less than 20kDa can be directly transported from
the nasal cavity to the CSF [98]. Finally, KA may reach the
hippocampus via the blood circulation [99].
5. Potentials of Antiglutamate Excitotoxicity as
aT h e rape u ticT arg et
Considering the importance of oxidative stress in KA-
induced excitotoxic damage, antioxidant and anti-inﬂam-
matorytreatmentsmayattenuateorpreventtheneurodegen-
erative disorders involved glutamate excitotoxicity [100].
COX-2 inhibitors as a therapeutic drug for the neuronal
loss after KA treatment have been studied [57]. Selective
COX-2 inhibitors, for example, celecoxib, rofecoxib, NS398,
and SC58125, can suppress the synthesis of PGE(2), whereby
blocking hippocampal neuronal death [10, 58]. Free radical
scavengers (FRSs) are known to prevent neuronal loss
induced by excitotoxins [101, 102]. Edaravone (Ed), a
newly developed FRS [103], and melatonin, the pineal
secretory product [104], were potent to attenuate KA-
induced neuronal death, suppress lipid peroxidation, and
inhibit microglial activation. Sinapic acid (SA), a GABA (A)
receptor agonist, can attenuate KA-induced hippocampal
damage in mice via its anticonvulsive activity through
GABA(A)receptoractivationandradicalscavengingactivity
[102]. Tetramethylpyrazine (TMP), a principal ingredient
of Ligusticum wallichi Franchat (a Chinese herb), can
function as a reductant/antioxidant to quench ROS, block
lipid peroxidation, and protect enzymatic antioxidants such
as glutathione peroxidase and glutathione reductase [105].
TMP may prevent and rescue KA-induced neuronal loss via
the preservation of the structural and functional integrity of
mitochondria, evidenced by maintaining the mitochondrial
membrane potential, ATP production, and complex I and III
activities [106].
Preclinical data have suggested KARs as an attractive tar-
get for drug development. Tezampanel, a nonselective KAR
inhibitor, can reduce migraine pain and other symptoms in6 Journal of Biomedicine and Biotechnology
a clinical phase II study. This suppressive eﬀect is probably
attributable to the inhibition of KARs. Another KAR antag-
onist, NS1209, can alleviate refractory status epilepticus and
neuropathic pain in phase II trials, but further research on
this agent has been suspended [107]. Tat-GluR6-9c, a GluR6
C-terminus peptide conjugated to a Tat peptide, confers
neuroprotection against neuronal death induced by KA-
induced excitotoxic brain injury without perturbing KAR-
mediated currents. This is mediated by its inhibition of JNK
activation [15, 108, 109].
Expression of p27, a cyclin-dependent kinase inhibitor
which arrests cell cycle at G1-S phase, was downregulated
in the neuronal cell death caused by several reasons like
glutamate toxicity [110]. It is demonstrated that reduced
expression of endogenous p27 induced cell death in cultured
corticalneuronsbytransfectionofp27smallinterferingRNA
(siRNA) [111]. p27 may alleviate KA-induced seizure and
hippocampal degeneration [112]. Early calpain activation
is involved in neurotoxicity in the hippocampus after KA
insults. Treatment with the calpain inhibitor MDL 28170
signiﬁcantly suppressed the neurodegeneration induced by
KA [113]. The roles of the activation of caspases and p21
in the process of neuronal death caused by KA insult have
been reported in several studies. However, it is still unclear
whether caspases and p21 are involved in KA-induced
neurodegeneration, as evidence by negative and conﬂicting
ﬁndings [114, 115].
5.1. Limitations of KA-Induced Neurodegenerative Model.
Notwithstanding the advantages of KA-induced model in
neurodegenerative studies, potential limitations should be
recognized. KA-induced neurodegeneration in animals is
an acute monophasic disorder, which diﬀers from chronic
neurodegenerative disorders in clinic. An alternative way to
induce the chronic model, that is, long-term administration
of KA at a lower dose, cannot mimic the pathogenesis
of neurodegeneration adequately. This is evidenced by the
fact that monosodium glutamate, a frequently added ﬂavor
enhancer, does not increase the incidence of neurodegener-
ative disorders. Despite a widespread belief that glutamate
may elicit Chinese Restaurant Syndrome (CRS), migraine
headache, and asthma, literature reviewing does not suggest
that individuals may be uniquely sensitive to glutamate
[116]. This might be partially explained by the dose-
dependent eﬀects of excitatory amino acids in the CNS.
The implications of excitatory amino acid transmitters are
complex. It may only represents one of several pathways
involved in pathological cell death, but not necessarily
the predominant or decisive one. Interventions targeted
at glutamate excitotoxicity are promising, yet to be with
caution,becauseiGluRsrepresentoneofthemajorexcitatory
neurotransmitter pathways in the physiological functions of
the brain, and the blockade of iGluRs might be disastrous to
the CNS functions.
Moreover, mouse strains vary signiﬁcantly in their sen-
sitivity to KA-induced neurodegeneration [117]. In general,
the C57BL/6, C57BL/10, and F1 C57BL/6∗CBA/J strains of
mice are resistant to systemic administration of KA, while
the FVB/N, ICR and DBA/2 J strains are vulnerable [19].
Since intranasal administration can break the tolerance to
KA in C57BL/6 mice, as demonstrated by Chen et al. [94],
administration routes should be carefully selected when
resistant strains are used. Thus, pilot studies are always
indispensable;otherwise,theresultsmightbeconfoundedby
the resistance.
Despite the theoretical or preclinical signiﬁcance of
KARs, concerns regarding the clinical prospects of drugs
targeting AMPARs and KARs prevail. This is due to the fact
that interference with excitotoxicity is accompanied unduly
witheﬀectsonsynaptictransmission.Therecentdiscoveryof
proteinsthatanchorandinteractwithiGluRspromisesanew
strategy to cytoprotective therapy without interfering with
synaptic transmission. The reason why iGluRs interactors
appearmoresuitableastherapeutictargetsthanthereceptors
per se is that they might interfere speciﬁcally with excitotoxic
pathways while leaving synaptic transmission untouched
[118]. Also, the relationship between the structure and
physiological functions of KARs is diﬃcult to study in the
CNS because of the large number of subunits of iGluRs,
their widespread distribution, and neuronal heterogeneity
[119, 120].
6. Concluding Remarks
Excitotoxicity is considered to be a major mechanism
involved in cell death of various CNS diseases including neu-
rodegenerative disorders. In the past decades, great progress
has been made in elucidating excitatory signaling pathways
whereasthe mechanism by which excitatory amino acids and
their receptors are implicated in neurodegenerative diseases
remains little known. KA-mediated excitotoxicity has long
been used as a model for elucidating mechanisms underlying
oxidative stress and inﬂammation in neurodegenerative
disorders. However, the routes of KA administration should
be taken into account, especially for those strains resistant to
conventional ways of administration.
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